MRNA
Moderna, Inc.
NASDAQ · Healthcare · Biotechnology · US
$154.04
−2.55%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$158.36
From 52W high−11.66%
Volume19.99M
Market cap$61.50B
P/E (TTM)—
P/S (TTM)27.6x
Div yield—
Key dataSep 18, 2026
Open
$158.36
From 52W high
−11.66%
Volume
19.99M
Market cap
$61.50B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−20.4x
P/E (TTM)
—
RSI (14)
63.6
MomentumView details →
1D Return
−2.55%
YTD Return
+423.98%
SummaryUpdated Jun 1, 2026
Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company founded in 2010 and headquartered in Cambridge, Massachusetts. The company went public in December 2018 and gained global prominence during the COVID-19 pandemic as one of the first companies to develop and commercialize an mRNA-based vaccine. Originally founded as Moderna Therapeutics, the company changed its name to Moderna, Inc. in August 2018. Today, Moderna has evolved from a single-product COVID vaccine company into a multi-product biotechnology firm with an expanding pipeline of mRNA-based therapeutics and vaccines across multiple disease areas.
Similar companies
Latest newsMore news →
Moderna's stock price reached a four-week high, with its latest gain at 8%.3d agoThe US Food and Drug Administration approved Moderna's mFLUSIVA, the first mRNA-based influenza vaccine, for adults aged 50 and older.4d agoModerna (MRNA) shares closed at $146.69, up 1.89% from the prior session, outperforming a 0.48% decline in the S&P 500, a 0.29% drop in the Dow and a 0.56% drop in the Nasdaq.6d ago